As the last resort and one of the most crucial antibiotics for multidrug-resistant bacteria, carbapenem is considered the best hope for treating bacterial infections. However, the prompt emergence of carbapenemase-producing bacteria (CPB) poses a striking global health threat. Thus, accurate and rapid methods for the detection of carbapenemase are being requested to guide precise diagnosis, appropriate treatment strategies, and antibiotic stewardship. Although genotypic, phenotypic, and biochemical methods are currently used in clinical practice for CPB detection, they each have their problems that cannot commendably meet the need. In recent years, small-molecule probes have made significant progress and breakthroughs in the rapid detection and subtyping of CPB, providing insights and innovative solutions for the ultra-sensitive detection of CPB. In this minireview, some of the advances, namely, chromogenic probes and methods, fluorogenic probes, dual fluorogenic–chromogenic probes, a chemiluminescent probe, and a novel label-free intracellular calorimetric approach, are summarized, appreciated, and discussed. These methods offer high sensitivity, specificity, and accuracy in a short period in clinical settings without the utilization of sophisticated equipment or professional personnel. We hope that this minireview can provide a reference for the development of rapid detection of CPB and eventually contribute to antibiotic resistance management.

Lipid droplets (LDs), once regarded as inert fat particles, have been ignored by scientific researchers for a long time. Now, studies have shown that LDs are dynamic organelles used to store neutral lipids in cells and maintain cell stability. The abnormality of intracellular LDs usually causes metabolic disorders in the body, such as obesity, atherosclerosis, diabetes, and cancer, so the LDs have attracted wide attention. The traditional small molecules used for LDs recognition seriously affect the imaging effect due to their poor photo-stability, low signal-to-noise ratios, and aggregation-induced quenching (ACQ). In contrast to ACQ, aggregation-induced emission (AIE) materials, with structural modifiability, can make up for the aforementioned deficiencies in the field of fluorescence imaging and have attracted much attention. In this review, the importance of LDs in vivo, the design principles for LDs recognition, and the recent research progress of AIE compounds with tetraphenylethene (TPE) structure in LDs targets are reviewed. We expect this review to further provide researchers with feasible methods and protocols for expanding LDs identification, imaging, and other applications.

The design of novel aggregation-induced emission (AIE)-active molecules represents a cutting-edge strategy for integrated phototheranostics in the second near-infrared (NIR-II) window. This review systematically outlines rational molecular engineering approaches based on D-A, D-A-D, and A-D-A systems to achieve red-shifted NIR-II absorption/emission, enhanced AIE characteristics, and balanced radiative and non-radiative decay pathways. These AIEgens enable high-contrast NIR-II fluorescence imaging (FLI) and photoacoustic imaging (PAI) for precise tumor localization, while concurrently facilitating efficient photothermal therapy (PTT) and robust photodynamic therapy (PDT) through both type-I and type-II mechanisms. Nanoformulations of these molecules exhibit excellent stability, biocompatibility, and passive targeting via the enhanced permeability and retention (EPR) effect. We further highlight representative “all-in-one” AIE platforms that demonstrate synergistic PTT/PDT under multimodal imaging guidance, offering a promising paradigm for precision cancer theranostics. Challenges and future directions in clinical translation and combination therapy are also discussed.